Member Info for matarakz

Ggp is almost a billion market cap without producing gold and MTl is only about 60 million
Market cap producing between 60-80,000 ounce a year with very low cost to produce . There is also significant amount of molybdenum to produce.

Imo, before u invest let the dust settle first and wait for the bottom, it may take days before it it finds its bottom. It is very volatile at the moment. Let the swing traders do their job. Still the fundamentals are still the same.

Powerful short attacks by hedge funds!

I bought more as long as the fundamentals are great and i’m always patient.

Well the big boys aka fund managers are buying now because of the fundamentals of the company. Patience is virtue.

Imo, in 3 years time Novacyt ‘s available cash would be more than £ 1 billion. That is why it is good to be a long term investor here. Dyor

I raised my target now from £15 to £30 . Hopefully I would hit may target by the end of the year. So far the best company in AiM and what we just need is Patience. Gl

€300 million revenue Target value-£13.6
€500 million revenue Target value- £30
Still very undervalued imo. Dyor

I’m very confident to say £10-15 next week. Patience is a virtue!

Initial valuation of the company at £13.50. Hoping for 10-15 next week. The best Aim company so far without thinking of ‘issue of equities’ which is common among Aim companies. No dilution to shareholders that is one big factor for investors.

Solgen’s market cap is more than £750 million against Ars’ markey cap of £62 million. Imo, very undervalued

This is just a warning to shorters. It does not work in a company with strong fundamentals.

This is a nice and healthy consolidation. Fundamentals are getting strong.

I’m hoping we would finish above £2 today. Very undervalued imo, Trump said monoclonal antibody is a cure against covid 19 infection.

The problem with antigen using saliva is the sensitivity . It cannot detect asymptomatic patients. It is the same with Abbott. That is why avacta is struggling to validate the test
Imo. Saliva using Pcr is still the gold standard.

Where is Pineapple now?Did he sold prematurely?

If we compare Qiagen’s market cap to its revenue it’s about x5-7. Then applyling it to Novacyt’s conservative revenue of
£300 million x 5-7. My estimate market cap should be at least £1. 5 billion equivalent to at least £20 per share. Dyor

Pmo was taken over very cheaply. The long term debt is a big problem for the company.

Fab is developing therapeutic neutralising antibodies, President Donald Trump was treated with Regeneron’s neutralising antibodies. It is a good sentiment for Covid play companies which are developing therapeutics against Covid 19. Good news for FAB and for investors Patience is always a virtue.

More contracts were already awarded to Novacyt, therefore the forecast for yearend revenue has increased as well. Imo, another additional £150 million to the projected £150 million revenue. Therefore personally my Projected yearend revenue is >£300 million and > £150 million net profit. More than £1 billion market cap is already justified with this figures. Dyor